Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > COLUMN
COLUMN
- Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
- Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
- An Insider’s Perspective on Hiring in Japan
April 26, 2013
- Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
- Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
- Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
- What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
- Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
- Leading from Afar
October 22, 2012
- “Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
- Our Habits Determine Our Success
August 8, 2012
- Marketing Is More than a Pen and a Tissue Box
July 9, 2012
- Science without Works Is Dead
June 4, 2012
- Social Networking in Japan’s Pharmaceutical Industry
May 1, 2012
- The Eight Characteristics of a Great Leader
April 2, 2012
- Maurer’s Healthcare Insight (143)
March 26, 2012
- Maurer’s Healthcare Insight (142)
February 27, 2012
- Maurer’s Healthcare Insight (141)
January 30, 2012
- Maurer’s Healthcare Insight (140)
December 26, 2011
- Maurer’s Healthcare Insight (139)
December 12, 2011
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…